Castle Biosciences
CSTL
130 hedge funds and large institutions have $317M invested in Castle Biosciences in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 70 increasing their positions, 25 reducing their positions, and 34 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 25
2.94% more ownership
Funds ownership: 83.12% → 86.07% (+2.9%)
12% less funds holding
Funds holding: 148 → 130 (-18)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $502M → $317M (-$185M)
51% less call options, than puts
Call options by funds: $325K | Put options by funds: $664K
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$26.9M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.23M |
| 3 |
Millennium Management
New York
|
+$4.26M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.11M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.3M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$10.9M |
| 3 |
GF
Greenhouse Funds
Baltimore,
Maryland
|
-$6.96M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.47M |
| 5 |
DM
Deerfield Management
New York
|
-$6.18M |
CSTL Hedge Fund Activity: Q2 2023 in Review
130 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2023, worth a combined $317M — down 37% from $502M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CSTL and 16 opened new positions — a net loss of 18 holders — while 25 trimmed existing stakes and 70 added.
The largest buyer was Granahan Investment Management, adding an estimated $26.9M. The largest seller was Citadel Advisors, cutting an estimated $12.3M.
- 130 institutional investors held Castle Biosciences (CSTL) as of Q2 2023, down from 148 in Q1 2023.
- Funds reported $317M of Castle Biosciences stock for Q2 2023, down 37% quarter-over-quarter.
- 16 funds opened new Castle Biosciences positions in Q2 2023 and 34 closed out, a net change of -18 holders.
- The largest Castle Biosciences buyer in Q2 2023 was Granahan Investment Management, an estimated $26.9M added.
- The largest Castle Biosciences seller in Q2 2023 was Citadel Advisors, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2023.